Abstract
Bladder cancer - a propensity that is associated with high recurrence and mortality rates. Various molecular alterations are reflected by diverse cellular morphological manifestations and vast tumor heterogeneity. Many biomarkers have been described that have undergone clinical trials and are approved for clinical use, but most still remain investigational. The question how molecular markers can support surveillance of different patient groups is still a matter of controversy. However, it can be expected that major advancement in the understanding of molecular pathways involved in urothelial carcinogenesis will enable improved patient management. The scope of this review is to discuss the established diagnostic tests and urinary biomarkers and their application for screening and surveillance of bladder cancer.
Keywords: Bladder cancer, Biomarkers, Cytology.
Mini-Reviews in Medicinal Chemistry
Title:The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Volume: 16 Issue: 18
Author(s): Bernhard Grubmüller, Morgan Roupret, Alberto Briganti and Shahrokh F. Shariat
Affiliation:
Keywords: Bladder cancer, Biomarkers, Cytology.
Abstract: Bladder cancer - a propensity that is associated with high recurrence and mortality rates. Various molecular alterations are reflected by diverse cellular morphological manifestations and vast tumor heterogeneity. Many biomarkers have been described that have undergone clinical trials and are approved for clinical use, but most still remain investigational. The question how molecular markers can support surveillance of different patient groups is still a matter of controversy. However, it can be expected that major advancement in the understanding of molecular pathways involved in urothelial carcinogenesis will enable improved patient management. The scope of this review is to discuss the established diagnostic tests and urinary biomarkers and their application for screening and surveillance of bladder cancer.
Export Options
About this article
Cite this article as:
Grubmüller Bernhard, Roupret Morgan, Briganti Alberto and Shariat F. Shahrokh, The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance, Mini-Reviews in Medicinal Chemistry 2016; 16 (18) . https://dx.doi.org/10.2174/1389557515666150909141404
DOI https://dx.doi.org/10.2174/1389557515666150909141404 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidized Polysaccharides as Green and Sustainable Biomaterials
Current Organic Chemistry The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Medicinal Chemistry of Selective Neurokinin-1 Antagonists
Current Topics in Medicinal Chemistry Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases
Current Drug Targets Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking
Recent Patents on Anti-Cancer Drug Discovery Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Editorial [Clinical Applications of Advanced CT, MRI and Optical Imagings as Well as Spect]
Current Medical Imaging Squalamine as an Example of a New Potent Antimicrobial Agents Class: A Critical Review
Current Medicinal Chemistry